Sign In
Buy LIFE
$16.89
-0.375 (-2.17%)
At Close: Jun 03, 2026
A small pharmaceutical company has surged 137% in 2 days after positive results in trials for lung disease treatment
12:03pm, Tuesday, 14'th Sep 2021
aTyr says it plans to meet with the FDA to present its data on ATYR1923, a potential treatment for pulmonary sarcoidosis.
Why Did Wainwright Beef Up ATyr Pharma's Price Target?
03:24pm, Monday, 13'th Sep 2021
H.C. Wainwright increased the price target on ATyr Pharma (NASDAQ:LIFE) to $18 from $13, with the Buy rating unchanged, implying more than 120% upside. Today, the Company reported positive data fr
LIFE Stock: Why It Significantly Increased Today
01:05pm, Monday, 13'th Sep 2021
The stock price of aTyr Pharma Inc (NASDAQ: LIFE) significantly increased today. This is why it happened.
LIFE Stock: What Is the Clinical Trial News Sending aTyr Pharma Soaring?
01:04pm, Monday, 13'th Sep 2021
Today, some news of positive clinical trial results for one of aTry's leading drug candidates has sent LIFE stock surging. The post LIFE Stock: What Is the Clinical Trial News Sending aTyr Pharma Soar
Why Are ATyr Pharma's Shares Trading Higher Today?
09:52am, Monday, 13'th Sep 2021
ATyr Pharma Inc (NASDAQ: LIFE) has announced positive results from its Phase 1b/2a trial evaluating its lead therapeutic candidate, ATYR1923, in pulmonary sarcoidosis, a major form of interstitial lun
Trial met primary endpoint, ATYR1923 was safe and well-tolerated.
aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q2 2021 Results - Earnings Call Transcript
10:06pm, Tuesday, 10'th Aug 2021
aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q2 2021 Results - Earnings Call Transcript
Atyr Pharma (LIFE) Reports Q2 Loss, Lags Revenue Estimates
06:33pm, Tuesday, 10'th Aug 2021
Atyr Pharma (LIFE) delivered earnings and revenue surprises of -39.13% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
aTyr Pharma: Q2 Earnings Insights
04:28pm, Tuesday, 10'th Aug 2021
Shares of aTyr Pharma (NASDAQ:LIFE) fell in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 7.25% over the past year to ($0.64), which missed
aTyr Pharma Announces Second Quarter 2021 Results and Provides Corporate Update
04:00pm, Tuesday, 10'th Aug 2021
Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in mid-September 2021.
Pharmsynthez PJSC Secures RUB 800m With LDA Capital
01:00am, Thursday, 24'th Jun 2021
LOS ANGELES--(BUSINESS WIRE)---- $LIFE #CapitalCommitment--Russian listed pharmaceutical manufacturer, Pharmsynthez PJSC (MOEX:LIFE), secures 800 million rubles from global alternative investor, LDA C
aTyr Pharma to Host Virtual Key Opinion Leader Event on Current Treatment Options for Pulmonary Sarcoidosis
08:00am, Wednesday, 23'rd Jun 2021
Event will feature Dr. Daniel Culver, Director of the Interstitial Lung Disease Program at the Cleveland Clinic.
aTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody
04:30pm, Thursday, 10'th Jun 2021
Preclinical candidate is second to demonstrate selective blocking ability from in-house panel of antibodies targeting NRP2.
Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse
02:52pm, Sunday, 16'th May 2021
Genscript raised more than $1 billion from Hillhouse Capital in several different investments, including a $500 million commitment to Genscript's Legend Biotech CAR-T subsidiary. Shanghai Fosun Pharma
aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q1 2021 Results - Earnings Call Transcript
11:38pm, Thursday, 13'th May 2021
aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q1 2021 Results - Earnings Call Transcript
